Tagged with US

USA 80 orphan drugs (those drugs intended to treat diseases so rare that sponsors are reluctant to develop them under usual marketing conditions) were approved in the USA in 2017, a record year and more than double the 40 approved in 2016.   Orphan drug spending grew from 5 to 10%…

Turkey Imports and exports in Turkish pharma between 2010 and 2017. Pharmaceutical exports grew to a total of USD 898 million in 2017.   These charts show both the volume and value of imported and locally-produced drugs in the Turkish pharma market between 2010 and 2017. TL 13.33 billion (USD 2.57…

USA 59 novel drugs were approved in the USA in 2018, representing a leap from the 46 approved in 2017 and 22 approved in 2016. 19 of the 59 drugs (32 percent) have been designated ‘first-in-class’ and 34 of the 59 drugs (58 percent) were approved to treat rare or “orphan”…

Opinion Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In this article, he gives his predictions for the political landscape in healthcare for 2019.  The challenges for firms are painfully apparent—there is bipartisan support in the US to lower drug prices, a pervasive sense that traditional advocacy methods are failing in today’s political climate,…

Spain Juan Luis Fernández Balaguer, general manager of Laboratorios Combix, the Spanish affiliate of Zydus Cadila, shares the milestones achieved by the company since joining the group and its promising future as one of two European operations. Having formerly served as president of AESEG, he then goes on to offer expert…

USA PJ Brooks PhD, program director in the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) in the USA, highlights the importance of going beyond one disease at a time in clinical trials, some of the roadblocks that still remain…

France Professor Alexander Eggermont, general director of Gustave Roussy, gives insights into the transformation of the Hospital under his ten-year leadership mandate. He also explains the rationale behind creating Cancer Core Europe, a collaborative platform of Europe’s seven leading cancer institutes.   Our system brings between 3500 and 4000 patients into…

USA Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) weighs in on the issue of drug shortages in America.    An uncertain environment for generic manufacturers imperils the sustainability of patient access to low-cost generic medicines.   The unavailability of prescription medicines can cause physical suffering,…

France   LEEM – Les Entreprises du Médicament (Drug Companies)   Key people: Philippe Tcheng, President Philippe Lamoureux, Director LEEM is the French industry association which represents drug companies operating in France and is the most powerful professional organization of drug companies operating in the country. They represent more than 260 member companies,…

Korea Roger Zbinden, head of the Swiss Business Hub Korea, explains their efforts to raise the profile of the South Korean market for Swiss business. Dr Zbinden also provides his insights into opportunities that exist in the Korean market and explains why Korea need not follow the Swiss model in its…

USA David H. Crean, PhD, Managing Director for Objective Capital Partners, a leading investment banking advisory firm examines the venture investment activity in life sciences for the past year.    In order to have a successful life sciences R&D program, biotech and pharma companies must develop game-changing therapeutics, companion diagnostics and personalized…

USA With an increasing number of NFL players relying on potentially dangerous prescription painkillers, does the league need to relax its attitude to medical cannabis?   The US National Football League (NFL) is a juggernaut. Even with decreased television ratings in 2017, the league’s revenue was up. Each of the NFL’s…